"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01) | PA 16 426

Opportunity Information: Apply for PA 16 426

This National Institutes of Health (NIH) grant opportunity (Funding Opportunity Number PA-16-426) is an R01 research project grant focused on cancers that occur in people living with HIV or AIDS, with particular emphasis on non-AIDS-defining malignancies. The central goal is to push the science forward on why these cancers occur, how they develop and progress, how they can be detected and diagnosed more effectively, and how they can be treated in the context of HIV infection. The announcement highlights that non-AIDS-defining cancers have become a leading cause of death among HIV-infected individuals, which makes understanding and addressing these malignancies an urgent public health need.

The research scope is broad and encourages projects that address high or medium priority AIDS-related cancer questions. Examples of encouraged topic areas include identifying etiologic factors and cofactors (such as viral coinfections, behavioral or environmental exposures, and treatment-related influences), clarifying immunopathogenesis (how HIV-associated immune dysfunction and immune activation contribute to cancer initiation and progression), improving diagnosis and clinical characterization of malignancies in HIV-positive populations, and studying the consequences of these cancers for patient outcomes and survivorship. The FOA supports work across both non-AIDS-defining cancers and traditional AIDS-defining cancers, as long as the work directly advances knowledge relevant to malignancies in people with underlying HIV infection.

The program is listed under CFDA numbers 93.121 and 93.393 and falls within the Education and Health funding activity categories. The funding instrument is a discretionary grant mechanism (R01), meaning it is intended for substantial, hypothesis-driven research projects that can produce rigorous, generalizable findings. While the source text does not provide an award ceiling or the expected number of awards, the R01 mechanism typically supports multi-year research efforts with clearly defined aims, a strong scientific premise, and an approach appropriate to the complexity of cancer and HIV comorbidity research.

Eligibility is intentionally expansive to encourage participation from a wide range of organizations capable of conducting biomedical, clinical, behavioral, and population-based research. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other entities. The FOA also specifically calls out additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). This broad eligibility signals an interest in diverse perspectives, varied research settings, and studies that may involve international populations or cross-regional collaborations where HIV-associated cancer burdens are significant.

Key administrative details include an original closing date of 2019-09-07 and a creation date of 2016-09-07, indicating the FOA was issued to support continuing research efforts during that period. Overall, the opportunity is designed for investigators and institutions seeking to address the changing cancer landscape in the HIV population, especially the rising importance of non-AIDS-defining malignancies, by generating evidence that can improve prevention strategies, diagnostic pathways, and treatment approaches tailored to people living with HIV.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled ""High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.393.
• This funding opportunity was created on 2016-09-07.
• Applicants must submit their applications by 2019-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PA 16 426

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: